Unicycive Therapeutics (UNCY) EBITDA Margin (2022 - 2023)
Unicycive Therapeutics' (UNCY) quarterly EBITDA Margin came in at 622.52% in Q1 2023, down 6.59% on a QoQ basis from 584.02% in Q3 2022.
Unicycive Therapeutics (UNCY) EBITDA Margin (2022 - 2023) Analysis & Trends
Unicycive Therapeutics (UNCY) has 2 years of EBITDA Margin data on file, last reported at 622.52% in Q1 2023.
- Quarterly EBITDA Margin changed N/A year-over-year to 622.52% in Q1 2023, while the trailing twelve-month figure through Dec 2023 was 3077.78% (changed N/A YoY) and the FY2023 annual result came in at 3077.63%, down 117942.0% from the prior year.
- EBITDA Margin declined to 622.52% in Q1 2023, from 584.02% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 584.02% in Q3 2022 to a low of 622.52% in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.29 Bn | 131.44 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 59.49 Bn | 54.36 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 42.02 Bn | 36.92 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.79 Bn | 27.48 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.26 Bn | 9.87 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.30 Bn | 26.14 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.10 Bn | 26.26 Bn | - | 19.75% |
| 10 | Unicycive Therapeutics | 151.01 Mn | 151.01 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | -622.52% |
| Sep 30, 2022 | -584.02% |